AUS
NZ
UK
CA
USA
IND
Highlights:
- Abivax (NASDAQ:ABVX) has announced its 2025 financial communications calendar.
- The schedule includes key reports such as the 2024 Annual Business and Financial Report and Q1, Half-Year, and Q3 reports.
- All financial reports will be released after US market closure, accompanied by regulatory filings for both Euronext and US markets.
Abivax, a clinical-stage biotechnology company specializing in therapies for chronic inflammatory diseases, has revealed its 2025 financial communications schedule. The timeline is important for stakeholders, offering a clear structure for the release of key reports and documents throughout the year. The company’s emphasis remains on providing transparent financial information and fulfilling its regulatory obligations on both the Euronext and US markets.
Annual Business and Financial Report
Abivax's 2024 Annual Business and Financial Report will be released alongside the Universal Registration Document. This report is essential for understanding the company's overall performance in the previous year, including its financial results and business milestones. The comprehensive document will also include the Annual Report on Form 20-F, which adheres to US regulatory requirements. All of these materials will be published after the US market closes, allowing for immediate access to the relevant financial data.
Quarterly Financial Results
Abivax will release its first-quarter financial results in early June, continuing its commitment to providing timely updates on its financial performance. The Q1 report will offer insight into the company’s financial health and progress in its research and development efforts. The company will follow up with its half-year financial report later in the summer, ensuring that stakeholders receive a mid-year update on the company’s financial standing.
Annual General Meeting
The company has also scheduled its Annual General Meeting (AGM) for the summer. The AGM is set to take place in Paris and will provide shareholders with the opportunity to engage with the company’s management and discuss its future direction. Shareholders will be able to vote on important matters and hear about the company’s strategies moving forward.
Q3 Financial Results
Abivax’s final financial communication for the year will be its third-quarter results, which are set for release in mid-December. This report will continue the company’s regular schedule of providing financial updates, ensuring that stakeholders are kept informed of the company’s performance as the year progresses.
Abivax’s financial calendar provides a transparent and consistent structure for stakeholders to access key financial reports and documents, helping to ensure continued transparency and regulatory compliance. The company's commitment to providing comprehensive financial data is an essential part of maintaining a strong relationship with its shareholders and market participants.
